Reviewing Sale of DePuy Synthes

Johnson & Johnson (J&J) is reportedly reviewing the sale of its orthopedics division, DePuy Synthes. Some analysts project that the deal size could exceed 20 billion dollars (approximately 29 trillion won).


Reuters Yonhap News Agency

Reuters Yonhap News Agency

View original image

Bloomberg News reported on the 19th (local time), citing sources, that "J&J is preparing documents and financial materials related to DePuy Synthes ahead of meetings with potential buyers in the coming weeks."


The sources also explained that several large private equity funds (PEFs) are considering forming a consortium to acquire the division. However, they added that the talks are still at an early stage and there is no guarantee that they will lead to an actual sale. J&J declined to comment on the matter.


In October last year, J&J announced a plan to separate its orthopedics division, whose growth has slowed, from the rest of the company’s operations, stating that it intended to complete the process within 18 to 24 months. DePuy Synthes, a division under J&J, provides implants and surgical equipment used in hip and knee replacement procedures. It generated sales of about 9.3 billion dollars last year.


Chief Financial Officer (CFO) Joseph Wolk said at the time that although the method of separation had not yet been finalized, the company was preparing for the possibility of a spin-off, the most time- and resource-intensive option. He also stated that if a sale or another type of transaction could create greater value, the company would be open to that, including "ideas that others might propose."



J&J has said that if DePuy Synthes is separated as an independent company, it would become the world’s largest orthopedics company. Bloomberg Intelligence estimated that the enterprise value of the orthopedics division, including debt, could reach about 28 billion dollars.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing